All stock lists
Ptc Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
Healthcare · Biotechnology
60.63+0.04 (+0.07%)
Insider Score
––Not scored
PTCT Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
PTCT analyst forecast
PTCT analyst consensus
Moderate Buy5 ratings
Buy 4 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
PTCT 12-month price target
$113.50+87.2% upsideaverage of 2 firms
$137.00High
$90.00Low
Best analysts covering PTCT
- Wells Fargo100%success rate · 5 calls
- RBC Capital100%success rate · 4 calls
- Cantor Fitzgerald76%success rate · 21 calls
- Morgan Stanley75%success rate · 4 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
PTCT analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| UBS | — | $90.00 | +50.8% | — | 2026-10-15 | |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2026-10-08 |
| Cantor Fitzgerald | Overweight | $137.00 | +106.8% | Reiterated | 2026-09-22 | |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-14 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-08-13 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-07-31 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-07-31 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-07-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-07-16 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2026-07-07 |
| — | Jefferies | Buy | — | — | Upgraded | 2026-05-27 |
| — | TD Cowen | Buy | — | — | Upgraded | 2026-05-08 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-05-08 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2026-05-08 |
| — | Jefferies | Hold | — | — | Downgraded | 2026-03-30 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-02-23 |
| — | B of A Securities | Buy | — | — | Reiterated | 2026-02-20 |
| — | RBC Capital | Sector Perform | — | — | Reiterated | 2026-02-20 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-02-20 |
| — | Barclays | Overweight | — | — | Upgraded | 2026-01-28 |
| — | RBC Capital | Sector Perform | — | — | Downgraded | 2025-12-01 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-11-06 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-11-05 |
| — | Goldman Sachs | Sell | — | — | Reiterated | 2025-11-05 |
| — | Citigroup | Neutral | — | — | Reiterated | 2025-11-05 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-11-05 |
| — | TD Cowen | Hold | — | — | Reiterated | 2025-11-05 |
| — | Jefferies | Buy | — | — | Reiterated | 2025-10-28 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-09-03 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-08-20 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-08-20 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-08-20 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-08-08 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-08-08 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-08-08 |
| — | B of A Securities | Buy | — | — | Reiterated | 2025-07-29 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-07-29 |
| — | UBS | Buy | — | — | Reiterated | 2025-07-29 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-07-29 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-07-29 |
| — | Truist Securities | Buy | — | — | Reiterated | 2025-07-29 |
| — | Citigroup | Neutral | — | — | Reiterated | 2025-07-28 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-05-27 |
| — | B of A Securities | Buy | — | — | Upgraded | 2025-05-09 |
| — | Barclays | Equal Weight | — | — | Reiterated | 2025-05-08 |
| — | Citigroup | Neutral | — | — | Upgraded | 2025-05-07 |
| — | Baird | Outperform | — | — | Reiterated | 2025-05-07 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-05-07 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-05-07 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-05-07 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-04-22 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-03-31 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-03-14 |
| — | B of A Securities | Neutral | — | — | Upgraded | 2025-03-11 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-02-28 |
| — | RBC Capital | Outperform | — | — | Reiterated | 2025-02-18 |
| — | Citigroup | Sell | — | — | Reiterated | 2025-02-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-02-03 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-01-15 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2024-12-13 |
PTCT earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-19 | -0.21 | -1.67 | $279.5M | $164.7M |
| 2026-05-07 | -0.45 | -0.03 | $217.4M | $272.6M |
| 2026-07-30 | 0.24 | 0.92 | $298.6M | $360.5M |
| 2026-10-29 | 0.21 | 0.00 | $304.6M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.